comparemela.com

Latest Breaking News On - Amicus therapeutics chart - Page 1 : comparemela.com

Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) at the 20th Annual WORLDSymposium

08.02.2024 - - Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease -PRINCETON, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) - Amicus Therapeutics (Nasdaq: FOLD), today announced that WORLDSymposium has . Seite 1

Drug administrationNew treatment awardAmicus therapeutics chartMicus therapeutics kursMicus therapeutics aktie

Amicus Therapeutics to Present at the 42nd Annual J P Morgan Healthcare Conference

03.01.2024 - PRINCETON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) - Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, .

San franciscoUnited statesBradley campbellAmicus therapeuticsChief executive officerHealthcare conferenceAmicus therapeutics chartMicus therapeutics kursMicus therapeutics aktie

Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

21.08.2023 - Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) - Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, . Seite 1

United statesDaphne quimiBradley campbellSimon harfordAmicus therapeuticsRetire at yearChief financial officerExecutive officerExecutive teamChief financialAmicus therapeutics chartMicus therapeutics kursMicus therapeutics aktie

vimarsana © 2020. All Rights Reserved.